A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Lin, Guimiao ^a   Wang, Xiaomei ^a   Yi, Wanxian ^a   Zhang, Chuanxia ^a   Xu, Gaixia ^b   Zhu, Xiaomei ^b   Cai, Zhiming ^a   Liu, Yu ^a   Diao, Yuwen ^a   Lin, Chia Mi M ^a   Jin, Guangyi ^a  

^a Shenzhen University School of Medicine   (China)

^b SHENZHEN UNIVERSITY   (China)

Author keywords

Embryonic carcinoma; Immunotherapy; OCT4; TLR7 agonist

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 12; OCTAMER TRANSCRIPTION FACTOR 4; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 7 OCTAMER BINDING TRANSCRIPTION FACTOR 4 CONJUGATE; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; POU5F1 PROTEIN, MOUSE; RECOMBINANT PROTEIN; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD EXAMINATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; COVALENT BOND; CYTOKINE RELEASE; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; EMBRYONAL CARCINOMA; IMMUNOCYTOTOXICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN PURIFICATION; SPLEEN LYMPHOCYTE; TESTIS CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CARCINOMA, EMBRYONAL; CHEMISTRY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE; MALE; METABOLISM; METASTASIS; SPLEEN; TESTICULAR NEOPLASMS; TIME FACTOR;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA, EMBRYONAL; CD8-POSITIVE T-LYMPHOCYTES; INTERFERON-GAMMA; INTERLEUKIN-12; LYMPHOCYTES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OCTAMER TRANSCRIPTION FACTOR-3; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TESTICULAR NEOPLASMS; TIME FACTORS; TOLL-LIKE RECEPTOR 7;

EID: 84930658276     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0524-y     Document Type: Article

References (29)

1. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med. 2002;195:1507-12.
2. Kim RJ, Nam JS. OCT4 Expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab Anim Res. 2011;27:147-52.
3. Zhu Z, Wen J, Zheng X, Wang D, Wang Q, Fan C. Expression of transcription factor Oct4 in bladder cancer cell line T24 and its effects on the biological characteristics of the cells. J Huazhong Univ Sci Technolog Med Sci. 2009;29:73-6.
4. Lin G, Zhao L, Yin F, Lan R, Li L, Zhang X, et al. TCF3 inhibits F9 embryonal carcinoma growth by the down-regulation of Oct4. Oncol Rep. 2011;26:893-9.
5. Dong Z, Zeng Q, Luo H, Zou J, Cao C, Liang J, et al. Increased expression of OCT4 is associated with low differentiation and tumor recurrence in human hepatocellular carcinoma. Pathol Res Pract. 2012;208:527-33.
6. Chang CC, Shieh GS, Wu P, Lin CC, Shiau AL, Wu CL. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res. 2008;68:6281-91.
7. Dhodapkar KM, Feldman D, Matthews P, Radfar S, Pickering R, Turkula S, et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A. 2010;107:8718-23.
8. Lengner CJ, Camargo FD, Hochedlinger K, Welstead GG, Zaidi S, Gokhale S, et al. Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell. 2007;1:403-15.
9. Lau SK, Chang KL. OCT4: a sensitive and specific immunohistochemical marker for metastatic germ cell tumors. Adv Anat Pathol. 2006;13:76-9.
10. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33:492-503.
11. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1:699-716.
12. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1:949-64.
13. Ma F, Zhang J, Zhang J, Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immuno. 2010;7:381-8.
14. Hamm S, Rath S, Michel S, Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol. 2009;6:257-65.
15. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. 2013;13:453-60.
16. Mifsud EJ, Tan AC, Jackson DC. TLR agonists as modulators of the innate immune response and their potential as agents against infectious disease. Front Immunol. 2014;5:79.
17. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
18. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218:74-86.
19. Chan M, Hayashi T, Kuy CS, Gray CS, Wu CC, Corr M, et al. Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem. 2009;20:1194-200.
20. Chan M, Hayashi T, Mathewson RD, Yao S, Gray C, Tawatao RI, et al. Synthesis and characterization of PEGylated toll like receptor 7 ligands. Bioconjug Chem. 2011;22:445-54.
21. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A. 2012;109:261-6.
22. Bernhardt SL, Gjertsen MK, Trachsel S, Moller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006;95:1474-82.
23. Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol. 2011;137:1337-42.
24. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67:1842-52.
25. Dawson NA, Roesch EE. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Expert Opin Biol Ther. 2014;14:709-19.
26. Wu CC, Hayashi T, Takabayashi K, Sabet M, Smee DF, Guiney DD, et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A. 2007;104:3990-5.
27. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A. 2005;102:15190-4.
28. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol. 2005;174:7676-83.
29. Oh JZ, Kedl RM. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J Immunol. 2010;185:4602-8.